

1,016 bone marrow biopsies from 699 individual patients. 892 Samples with molecular data (RNAseq or WES)	
Age, median (range), years	64 (30-92)
Gender	N (%)
Male	500 (56)
Female	392 (44)
ISS stage (specimen level)	N (%)
Total (Available Staging Data)	852 (96)
Stage I	550 (62)
Stage II	222 (25)
Stage III	80 (9)
Unavailable data	40 (4)
Cytogenetic abnormalities (risk data)	N (%)
Total (Available Risk Data)	557
High-risk ^a	96 (17)
Intermediate-risk ^b	165 (30)
Standard-risk ^c	207 (37)
Normal panel	89 (16)
Unavailable data	335
Cytogenetic abnormalities (molecular data)	N (%)
Total (Available Data)	557
t(11;14)	100 (18)
t(4;14)	48 (9)
amp(1q21)	206 (37)
del13q	223 (40)
del17p	86 (15)
Unavailable data	335
Disease status	N (%)
MGUS	77 (9)
SMOL	73 (8)
NDMM	215 (24)
ERMM	368 (41)
LRMM	159 (18)
Treatment history	median (range), years
Number of prior lines of regimens	2 (0-15)
Refractory to	N (%)
Bortezomib	114 (13)
Carfilzomib	61 (7)
Lenalidomide	136 (15)
Pomalidomide	67 (8)
Daratumumab	33 (4)

^aHigh-risk: del17p or t(14;16) or t(14;20)

^bIntermediate-risk: t(4;14) or amp(1q21)

^cStandard-risk: all other abnormalities

Supplemental Table 1. | Demographics and molecular characteristics of patients and samples in this study.